share_log

Cantor Fitzgerald Reiterates Neutral on Verve Therapeutics, Maintains $22 Price Target

Benzinga ·  Aug 29, 2023 12:04

Cantor Fitzgerald analyst Rick Bienkowski reiterates Verve Therapeutics (NASDAQ:VERV) with a Neutral and maintains $22 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment